Health Care·Pharmaceuticals·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.21 | N/A | -20.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.21 | N/A | -20.15% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management acknowledged the tough market conditions impacting performance. They remain committed to their long-term strategy.
Management highlighted ongoing challenges in the market but remains focused on long-term growth.
They emphasized the importance of strategic investments despite current pressures.
Phibro Animal Health's earnings report showed a miss on EPS, leading to a 2.5% decline in stock price. Investors may be concerned about the company's ability to navigate current market challenges. The lack of revenue data and forward guidance adds uncertainty for future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Nov 7, 2022